Clinical trialNCT02637960CompletedPhase 2/PHASE3Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

SponsorVantia LtdEnrollment432Nocturia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Marc Gittelman, MD, FACS
South Florida Medical Research
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Vantia Investigative Center
Anniston, Alabama, United States
Vantia Investigative Center
Goodyear, Arizona, United States
Vantia Investigative Center
Lincoln, California, United States
Vantia Investigative Center
Murrieta, California, United States
Vantia Investigative Center
San Diego, California, United States
Vantia Investigative Center
Aventura, Florida, United States
Vantia Investigative Center
Bradenton, Florida, United States
Vantia Investigative Center
Clearwater, Florida, United States
Vantia Investigative Center
Coral Gables, Florida, United States
Vantia Investigative Center
DeLand, Florida, United States
Vantia Investigative Center
Hialeah, Florida, United States
Vantia Investigative Center
Miami, Florida, United States
Vantia Investigative Center
Ocala, Florida, United States
Vantia Investigative Center
Pembroke Pines, Florida, United States
Vantia Investigative Center
St. Petersburg, Florida, United States
Vantia Investigative Center
Tampa, Florida, United States
Vantia Investigative Center
Avon, Indiana, United States
Vantia Investigative Center
Topeka, Kansas, United States
Vantia Investigative Center
Wichita, Kansas, United States
Vantia Investigative Center
Greenbelt, Maryland, United States
Vantia Investigative Center
Missoula, Montana, United States
Vantia Investigative Center
Omaha, Nebraska, United States
Vantia Investigative Center
Englewood, New Jersey, United States
Vantia Investigative Center
Lawrenceville, New Jersey, United States
Vantia Investigative Center
Albuquerque, New Mexico, United States
Vantia Investigative Center
Garden City, New York, United States
Vantia Investigative Center
New York, New York, United States
Vantia Investigative Center
Newburgh, New York, United States
Vantia Investigative Center
Poughkeepsie, New York, United States
Vantia Investigative Center
Cary, North Carolina, United States
Vantia Investigative Center
Concord, North Carolina, United States
Vantia Investigative Center
High Point, North Carolina, United States
Vantia Investigative Center
Raleigh, North Carolina, United States
Vantia Investigative Center
Wilmington, North Carolina, United States
Vantia Investigative Center
Winston-Salem, North Carolina, United States
Vantia Investigative Center
Akron, Ohio, United States
Vantia Investigative Center
Warwick, Rhode Island, United States
Vantia Investigative Center
Charleston, South Carolina, United States
Vantia Investigative Center
Greer, South Carolina, United States
Vantia Investigative Center
Mt. Pleasant, South Carolina, United States

8 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FedovapagonPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2016
Primary completion: 31 Jul 2017
Completion: 31 Aug 2017
Last update posted: 31 Oct 2018
Registered enrollment: 432
Registry id: NCT02637960

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.